ArticleCureus2026
Real-World Effectiveness and Safety of Tapinarof 1% Cream in Psoriasis: An Observational Study From Bangladesh.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Localized comedones and perifollicular hyperpigmentation during tapinarof cream therapy: a case series.Skin health and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Tapinarof 1% cream, a non-steroidal topical aryl hydrocarbon receptor (AhR) agonist, has demonstrated effectiveness in the treatment of psoriasis. However, real-world data from low-resource settings is scarce. This study evaluated the real-world effectiveness and safety of tapinarof 1% cream in adults with mild to moderate plaque psoriasis, and it explored differences in outcomes between tapinarof monotherapy and tapinarof combined with a moderately potent topical corticosteroid (clobetasone butyrate). Between-group comparisons were prespecified as exploratory and associative due to non-random allocation. Methods In this prospective observational study, 122 patients with confirmed plaque psoriasis received tapinarof monotherapy (n = 72) or combination therapy with topical corticosteroids (n = 50). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA) at baseline and at weeks 4, 8, and 12. PASI75 and PASI90 responses were analyzed using odds ratios (ORs) and 95% confidence intervals (CIs). Multivariable-adjusted and longitudinal sensitivity analyses were performed. Adverse events (AEs) were recorded. Results At week 12, mean PASI decreased from 6.02 ± 2.40 to 2.78 ± 1.28 in the monotherapy group (p = 0.045) and from 6.46 ± 2.06 to 1.38 ± 1.14 in the combination group (p < 0.001), with a significant between-group difference (p < 0.001). PASI75 was achieved by 30 (60.0%) patients in the combination group and 10 (13.9%) in the monotherapy group (OR = 6.25, 95% CI: 2.38-16.67; p < 0.001). PASI90 responses occurred in 14 (28.0%) and six (8.3%) patients, respectively (OR = 4.35, 95% CI: 1.52-12.50; p = 0.043). Mean changes in PGA differed between groups (p = 0.038). AEs were mild and similar across groups. Conclusion Combination therapy was associated with greater clinical improvement than tapinarof monotherapy in this observational cohort; however, these findings represent associations rather than causal effects, and the incremental contribution of tapinarof cannot be isolated because the combination arm included topical corticosteroids. Randomized studies are required to confirm comparative effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.